Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin, Aurobindo...

    Lupin, Aurobindo Pharma recalls multiple lots of BP drug including VALSARTAN

    Farhat NasimWritten by Farhat Nasim Published On 2019-04-01T09:50:55+05:30  |  Updated On 16 Aug 2021 3:58 PM IST




    Aurobindo Pharma is also recalling certain lots of Amlodipine and Valsartan Tablets USP 10mg/160mg in 30 count bottles for CGMP deviations.

    New Delhi: Drug major Aurobindo Pharma is recalling multiple lots of blood pressure lowering drugs in the US after the American health regulator found certain deviations from Current Good Manufacturing Practice (CGMP) regulations. Besides, Mumbai-based Lupin is also recalling 3,200 bottles of Testosterone Topical solution in the US for issues with the container.

    As per the latest Enforcement Report issued by the US Food and Drug Administration (USFDA), Aurobindo Pharma USA Inc is recalling the drug in various strengths due to "presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the active pharmaceutical ingredient (API) which used to manufacture the product."

    The company, which is a subsidiary of Hyderabad-based Aurobindo Pharma, has initiated a voluntary recall for some lots of Valsartan tablets in strengths of 320 mg, 80 mg, 160 mg in 90 count bottles and 40 mg tablets in 30 count bottles.

    It is also recalling certain lots of Amlodipine and Valsartan Tablets USP 10mg/160mg in 30 count bottles for CGMP deviations.

    Aurobindo has distributed the product to major distribution chains throughout the US, USFDA said.

    The US health regulator has classified the action as a Class-II recall, which is initiated in a "situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote".

    Baltimore-based Lupin Pharmaceuticals Inc, a part of Lupin, is also recalling 3,200 bottles of Testosterone Topical Solution in the US.

    USFDA said repetitive complaints were received regarding the container indicating faulty pump.

    The product was distributed to seven major wholesale/drug chain distributors and one supermarket chain that may have further distributed the product throughout the US, USFDA said in its report.

    The US health regulator classified it as class III recall, which is initiated in a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.





    Also Read: Lupin launches generic version of Lidex Ointment

    Active Pharmaceutical IngredientAurobindo Pharmablood pressureblood pressure lowering drugsEnforcement ReportLupinLupin Pharmaceuticals IncN-nitrosodiethylamineNew Delhipharmapharma newspharma news indiaTestosterone Topical SolutionUS Food and Drug AdministrationUS marketUSFDAValsartanValsartan Tablets
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok